Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Uro
Special Issues
Uro-Oncology: Treatment and Future Directions
share announcement

Uro-Oncology: Treatment and Future Directions

A special issue of Uro (ISSN 2673-4397).

Deadline for manuscript submissions: closed (15 April 2024) | Viewed by 3515

Special Issue Editor

Dr. Bartosz Małkiewicz

E-Mail Website
Guest Editor
University Center of Excellence in Urology, Department of Minimally Invasive and Robotic Urology, Wroclaw Medical University, 50-556 Wroclaw, Poland
Interests: uro-oncology; lymph node metastasis-growth and immune evasion; minimally invasive surgery; radio-guided surgery; prostate cancer; bladder cancer
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The incidence of urological malignancies has increased significantly over the last three decades. Kidney and bladder cancers and especially prostate cancer account for a significant percentage of all new cases in oncology. Even if in most cases the initial treatment is curable, a number of patients have a poor course of the disease with local or distant relapses and require further treatment, which significantly reduces their quality of life.

Over the past two decades, great efforts have been made to improve diagnosis and treatment outcomes. Molecular biomarkers have been investigated and introduced into clinical practice, and new pathological and clinical classifications have been proposed to account for the tumor behavior and risk of disease recurrence. At the same time, new surgical and pharmacological approaches have been developed to improve treatment outcomes.

Nevertheless, many topics remain a matter of debate regarding accurate diagnosis, targeted therapy, and multidisciplinary management.

This Special Issue of Uro will cover all aspects of urological cancers, including original research into advanced imaging, molecular characterization, current and experimental treatment options, and quality of life. Research articles, expert opinions, systematic reviews, and meta-analyses are also welcome.

Dr. Bartosz Małkiewicz
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Uro is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • genitourinary malignancy
  • prostate cancer
  • bladder cancer
  • kidney cancer
  • upper urinary tract tumors
  • testicular tumors
  • novel tumor markers
  • diagnosis
  • radical treatment
  • systemic treatment
  • immunotherapy
  • hormonal treatment
  • radiotherapy

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

Jump to: Other

15 pages, 590 KiB  
Review
Evolving Treatment Options for Metastatic Renal Cell Carcinoma (mRCC)
by Eun-mi Yu, Mythri Mudireddy, Ishan Patel and Jeanny B. Aragon-Ching
Uro 2023, 3(2), 117-131; https://doi.org/10.3390/uro3020014 - 01 Apr 2023
Cited by 2 | Viewed by 1994
Abstract
Approximately a third of patients diagnosed with kidney cancer in the United States present with advanced disease and those who present with distant metastases historically had dismal 5-year relative survival. However, over the last several years, advancements have led to improved life expectancy [...] Read more.
Approximately a third of patients diagnosed with kidney cancer in the United States present with advanced disease and those who present with distant metastases historically had dismal 5-year relative survival. However, over the last several years, advancements have led to improved life expectancy and patient outcomes in those who develop advanced renal cell carcinoma. Metastatic clear cell renal cell carcinoma (mccRCC) treatment has rapidly evolved with multiple drug approvals since 2006. Moreover, multiple combination regimens including a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI) plus immune checkpoint inhibitor (ICI) and the combination of ipilimumab plus nivolumab have supplanted first-line VEGF-TKI monotherapy. Thus, the insights we gained from prospective randomized controlled trials focusing on systemic therapy beyond first-line therapy in mRCC patients treated in the TKI monotherapy era quickly became less relevant with the adoption of contemporary first-line combination regimens. Herein, we will review contemporary first- and second-line therapies for mccRCC, as well as highly anticipated clinical trials looking into novel regimens beyond first-line therapy in patients who have received combination therapy. Full article
(This article belongs to the Special Issue Uro-Oncology: Treatment and Future Directions)
►▼ Show Figures

Figure 1

Other

Jump to: Review

10 pages, 252 KiB  
Case Report
Adult-Type Granulosa Cell Tumor of the Testis: A Report of a Case and a Discussion of the Literature
by Georgios Zervopoulos, Nikolaos Mitsimponas, Filippos Venetsanos and Athanasios Papathanasis
Uro 2023, 3(3), 177-186; https://doi.org/10.3390/uro3030019 - 03 Jul 2023
Viewed by 1055
Abstract
Testicular granulosa cell tumors (TGCTs) are rare tumors of sex cord-stromal origin. TGCTs are classified into two main categories, the adult type and the juvenile type. The adult type is extremely rare, with only 93 known cases reported in the literature. Herein, we [...] Read more.
Testicular granulosa cell tumors (TGCTs) are rare tumors of sex cord-stromal origin. TGCTs are classified into two main categories, the adult type and the juvenile type. The adult type is extremely rare, with only 93 known cases reported in the literature. Herein, we present a report of a case of a 30-year-old male patient who presented with a testicular mass and underwent radical inguinal orchiectomy; the pathology examination revealed an adult-type granulosa tumor. Additionally, we review the literature to summarize the scientific knowledge of an entity barely described worldwide. Full article
(This article belongs to the Special Issue Uro-Oncology: Treatment and Future Directions)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop